The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice
Xiaoxin X. Wang(Georgetown University), Moshe Levi(Georgetown University), Andrew E. Libby(Georgetown University), Komuraiah Myakala(University of Colorado Anschutz Medical Campus), Stephen M. Hewitt(National Institutes of Health), Suman Ranjit(Fluor (United States)), David E. Kleiner, Avi Z. Rosenberg, David J. Orlicky(University of Colorado Anschutz Medical Campus), Shogo Takahashi(National Institutes of Health), Diana Ir(University of Colorado Anschutz Medical Campus), Jeffrey B. Kopp(Kidney Care UK), Jonathan Levi(National Institutes of Health), Kanchan Bhasin(Georgetown University), Yuhuan Luo(University of Colorado Anschutz Medical Campus), Charles E. Robertson(Duke University), Luciano Adorini(Intercept Pharmaceuticals (United States)), Kristopher W. Krausz(National Institutes of Health), Daniel N. Frank(University of Colorado Denver), Frank J. Gonzalez(National Institutes of Health), James L. McManaman(University of Colorado Anschutz Medical Campus), Bryce A. Jones(Georgetown University), Cen Xie(Shanghai Institute of Materia Medica), Alexander Dvornikov(Fluor (United States)), Enrico Gratton(University of California, Irvine)
Cited by 55
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity
|Science|2013|2k
The Phasor Approach to Fluorescence Lifetime Imaging Analysis
|Biophysical Journal|2007|1.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k